{"product_id":"lucitala-1-talazoparib-люцитала-1-талазопариб","title":"LuciTala 1 (Talazoparib)            ЛюциТала 1 (талазопариб)","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eLuciTala 1 (Talazoparib)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anticancer medicine containing \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003etalazoparib\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a poly(ADP-ribose) polymerase (PARP) inhibitor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Talazoparib is used for the treatment of certain adults with \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eHER2-negative locally advanced or metastatic breast cancer\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e with a deleterious or suspected deleterious germline BRCA mutation. It may also be used in combination with enzalutamide for certain adults with metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) gene alterations, depending on the applicable product labeling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eMechanism of action:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Talazoparib inhibits PARP enzymes and traps PARP on DNA, interfering with DNA repair and leading to cancer-cell death, particularly in tumors with defects in homologous recombination DNA repair.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Capsules for oral administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eAdministration:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Taken orally once daily according to the prescribed treatment regimen. The dose may require adjustment based on kidney function, adverse reactions, or concomitant treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003ePossible adverse effects:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Common adverse reactions include anemia, neutropenia, thrombocytopenia, fatigue, nausea, headache, and decreased appetite. Serious risks may include myelosuppression and, rarely, myelodysplastic syndrome or acute myeloid leukemia.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Talazoparib is a prescription oncology medicine and should be used under the supervision of a qualified healthcare professional.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45405777395755,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/getImage.png?v=1789728599","url":"https:\/\/xomeds.com\/products\/lucitala-1-talazoparib-%d0%bb%d1%8e%d1%86%d0%b8%d1%82%d0%b0%d0%bb%d0%b0-1-%d1%82%d0%b0%d0%bb%d0%b0%d0%b7%d0%be%d0%bf%d0%b0%d1%80%d0%b8%d0%b1","provider":"XOMEDS","version":"1.0","type":"link"}